Distinct Genomic Landscapes in Early-Onset and Late-Onset Endometrial Cancer.

Abstract

The spectrum of somatic mutations among women with endometrial cancer (EC) younger than 50 years (early-onset EC) remains unknown. We investigated distinct somatic mutation patterns among early-onset and late-onset (age ≥ 50 years) EC patients. This cohort study included individuals age 18+ years diagnosed with pathologically confirmed EC in the American Association of Cancer Research (AACR) Genomics Evidence Neoplasia Information Exchange (GENIE, v9.1) consortium. We explored tumor mutational burden (TMB) and genomic patterns of EC by age at clinical sequencing using multivariable regression models adjusted for race, ethnicity, histology, sequencing assay, sample type, and TMB. Among 2,425 women with EC, 176 (7.3%) had early-onset EC and 1,923 (79.3%) had nonhypermutated (< 17.78 mutations/Mb) tumors. TMB significantly differed across age and histology groups. Among nonhypermutated ECs, early-onset patients had significantly lower odds of presenting with nonsilent <i>FGFR2</i> and <i>PIK3R1</i> somatic mutations compared with late-onset EC patients in adjusted models (<i>FGFR2</i>: odds ratio [OR] = 0.18, 95% CI, 0.04 to 0.76; <i>PIK3R1</i>: OR = 0.54, 95% CI, 0.31 to 0.92). By contrast, early-onset EC patients had increased odds of presenting with nonsilent <i>CTNNB1</i> and <i>BRCA2</i> mutations compared with late-onset patients (<i>CTNNB1</i>: OR = 3.32, 95% CI, 2.14 to 5.16; <i>BRCA2</i>: OR = 4.01, 95% CI, 1.55 to 10.38). Subsequent analyses stratified by race, ethnicity, and tumor histology identified distinct patterns of <i>APC</i>, <i>KMT2D</i>, <i>KMT2C</i>, and <i>KRAS</i> by race, ethnicity, and <i>PTEN</i> and <i>APC</i> patterns by histologic subtypes. Early-onset EC harbors a unique genomic landscape compared with late-onset disease. A distinct molecular phenotype of early-onset EC provides novel insights into a unique etiology and may yield clinical implications for developing targeted treatment modalities for younger patients.